These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33843859)

  • 1. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
    Wolf J; Fonseca R; Muffly L
    Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
    Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
    J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
    Derman BA; Fonseca R
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Diagnostics of Plasma Cell Neoplasms.
    Fitzpatrick MJ; Murali MR; Nardi V
    Surg Pathol Clin; 2023 Jun; 16(2):401-410. PubMed ID: 37149365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
    Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
    Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
    Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS
    Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):534-541. PubMed ID: 39134483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
    Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
    J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
    Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
    Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of minimal residual disease detection in multiple myeloma].
    Takamatsu H
    Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
    Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
    Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
    Tapia-Alveal C; Olsen TR; Worgall TS
    Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
    Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
    Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.